Tenofovir, boosted atazanavir and boosted lopinavir are associated with cumulative risk of developing chronic kidney disease
Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation
Starting HIV treatment at CD4 count above 500 reduces the risk of serious illness and death by 44%, African Temprano trial shows
XDR-TB in South Africa is largely spread person-to-person, not by failure of drug treatment
Stopping cotrimoxazole during antiretroviral therapy raises risk of bacterial illness, malaria, Ugandan trial shows
